Citations (70)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Gary J. Young, Md Mahmudul Hasan, Leonard D. Young & Md. Noor-E-Alam. (2023) Treatment Experiences for Patients Receiving Buprenorphine/Naloxone for Opioid Use Disorder: A Qualitative Study of Patients’ Perceptions and Attitudes. Substance Use & Misuse 58:4, pages 512-519.
Read now
Read now
Laura Checkley, Scott Steiger & Kelly R. Knight. (2022) “I wanted something that was more flexible”: A qualitative study of patient preferences on choosing buprenorphine over methadone in a large, safety-net hospital opioid treatment program. Substance Abuse 43:1, pages 767-773.
Read now
Read now
Kevin Baumgartner, Ellen Salmo, David Liss, Jason Devgun, Michael Mullins, Bridget Galati, Jeannie Kelly & Evan Schwarz. (2022) Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study. Clinical Toxicology 60:6, pages 688-693.
Read now
Read now
Élise Lachapelle, Léonie Archambault, Camille Blouin & Michel Perreault. (2021) Perspectives of people with opioid use disorder on improving addiction treatments and services. Drugs: Education, Prevention and Policy 28:4, pages 316-327.
Read now
Read now
Babak Tofighi, Arthur Robin Williams, Chemi Chemi, Selena Suhail-Sindhu, Vicky Dickson & Joshua D. Lee. (2019) Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care. Substance Use & Misuse 54:14, pages 2409-2419.
Read now
Read now
Yatan Pal Singh Balhara, Shalini Singh & Siddharth Sarkar. (2019) Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction. Substance Use & Misuse 54:2, pages 307-314.
Read now
Read now
Karen McElrath. (2018) Medication-Assisted Treatment for Opioid Addiction in the United States: Critique and Commentary. Substance Use & Misuse 53:2, pages 334-343.
Read now
Read now
Elizabeth E. Krans, Debra Bogen, Gale Richardson, Seo Young Park, Shannon L. Dunn & Nancy Day. (2016) Factors associated with buprenorphine versus methadone use in pregnancy. Substance Abuse 37:4, pages 550-557.
Read now
Read now
Articles from other publishers (62)
Katherine McLean, Jennifer Murphy & Nathan Kruis. (2024) “I think we're getting better but we're still not there”: Provider-based stigma and perceived barriers to care for people who use opioids (PWUO). Journal of Substance Use and Addiction Treatment 159, pages 209270.
Crossref
Crossref
Jessica J. Wyse, Alison Eckhardt, Dylan Waller, Adam J. Gordon, Sarah Shull, Travis I. Lovejoy, Katherine Mackey & Benjamin J. Morasco. (2024) Patients' Perspectives on Discontinuing Buprenorphine for the Treatment of Opioid Use Disorder. Journal of Addiction Medicine.
Crossref
Crossref
Terence Hughes, Nicholas Nasser & Avir Mitra. (2024) Overview of best practices for buprenorphine initiation in the emergency department. International Journal of Emergency Medicine 17:1.
Crossref
Crossref
Michael Hsu, Olivia S. Jung, Li Ting Kwan, Oluwole Jegede, Bianca Martin, Aniket Malhotra & Joji Suzuki. (2024) Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. Journal of Substance Use and Addiction Treatment 157, pages 209216.
Crossref
Crossref
Elizabeth J. Austin, Quentin E. O’Brien, Monica S. Ruiz, Anna D. Ratzliff, Emily C. Williams & Ulrich Koch. (2023) Patient and Provider Perspectives on Processes of Engagement in Outpatient Treatment for Opioid Use Disorder: A Scoping Review. Community Mental Health Journal 60:2, pages 330-339.
Crossref
Crossref
Pouya Azar, James S.H. Wong, Nickie Mathew, Martha J. Ignaszewski, Nilufar Partovi, Reinhard M. Krausz, Adedayo Ajidahun, Sahithi Thotakura, Marianne Harris, Rolando Barrios, Julio S.G. Montaner & Anil R. Maharaj. (2024) 48-hour Induction of Transdermal Buprenorphine to Extended-release Buprenorphine. Journal of Addiction Medicine 18:1, pages 82-85.
Crossref
Crossref
Utsha G. Khatri, Max Jordan Nguemeni Tiako, Abeselom Gebreyesus, Andre Reid, Sara F. Jacoby & Eugenia C. South. (2023) “A Lack of Empathy:” A qualitative study of Black people seeking treatment for opioid use disorder. SSM - Qualitative Research in Health 4, pages 100298.
Crossref
Crossref
James C. Miller, Michael A. Brooks, Kelly E. Wurzel, Emily J. Cox & John F. WurzelIIIIII. (2023) A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder. Drugs in R&D 23:4, pages 339-362.
Crossref
Crossref
Morica Hutchison, Beth S. Russell, Abigail Leander, Nathaniel Rickles, Derek Aguiar, Xiaomei S. Cong, Ofer Harel & Adrian V. Hernandez. (2023) Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis. Journal of Drug Issues.
Crossref
Crossref
Marnie Noel, Elizabeth Abbs, Leslie Suen, Lysa Samuel, Sarah Dobbins, Michelle Geier & Christine S. Soran. (2023) The Howard Street Method: A Community Pharmacy-led Low Dose Overlap Buprenorphine Initiation Protocol for Individuals Using Fentanyl. Journal of Addiction Medicine 17:4, pages e255-e261.
Crossref
Crossref
Margaret Lowenstein, Matthew P. Abrams, Molly Crowe, Kelsey Shimamoto, Silvana Mazzella, Denise Botcheos, Jennifer Bertocchi, Shawn Westfahl, Judy Chertok, Kristine Pamela Garcia, Rachael Truchil, M. Holliday-Davis & Shoshana Aronowitz. (2023) “Come try it out. Get your foot in the door:” Exploring patient perspectives on low-barrier treatment for opioid use disorder. Drug and Alcohol Dependence 248, pages 109915.
Crossref
Crossref
Hilary S. ConneryRoger D. Weiss. (2023) Drug Overdose Prevention: An Exercise in Optimism. American Journal of Psychiatry 180:5, pages 337-339.
Crossref
Crossref
Lakshmi Ganapathi, Allison M. McFall, Kimberly F. Greco, Aylur K. Srikrishnan, Muniratnam Suresh Kumar, Kenneth H. Mayer, Conall O’Cleirigh, Shruti H. Mehta, Gregory M. Lucas & Sunil S. Solomon. (2023) Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India. Drug and Alcohol Dependence 246, pages 109839.
Crossref
Crossref
Gemma Scott, Sophie Turner, Natalie Lowry, Annette Hodge, Waniya Ashraf, Katie McClean, Mike Kelleher, Luke Mitcheson & John Marsden. (2023) Patients’ perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study. BMJ Open 13:3, pages e069857.
Crossref
Crossref
Pouya Azar, James S.H. Wong, Nickie Mathew, Marc Vogel, Jeanmarie Perrone, Andrew A. Herring, Reinhard M. Krausz, Julio S.G. Montaner, Mark K. Greenwald & Anil R. Maharaj. (2023) 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method. Journal of Addiction Medicine 17:2, pages 233-236.
Crossref
Crossref
Rosemarie A. Martin, Nicole Alexander-Scott, Justin Berk, Ryan W. Carpenter, Augustine Kang, Ariel Hoadley, Eliana Kaplowitz, Linda Hurley, Josiah D. Rich & Jennifer G. Clarke. (2023) Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study. The Lancet Regional Health - Americas 18, pages 100419.
Crossref
Crossref
Hilary Luderer, Nicole Enman, Robert Gerwien, Stephen Braun, Samantha McStocker, Xiaorui Xiong, Carrington Koebele, Christopher Cannon, Joseph Glass & Yuri Maricich. (2023) A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study. JMIR Research Protocols 12, pages e43122.
Crossref
Crossref
Prachi H. Bhuptani, Amanda Block, Paola Jiménez Muñoz, Mariel S. Bello, Susan Ramsey, Megan Ranney, Kate Carey, Josiah Rich & Kirsten Langdon. (2023) Enhancing distress tolerance to uplift motivation in recovery: Results from an open development trial. DIGITAL HEALTH 9, pages 205520762311585.
Crossref
Crossref
Jessica J. Wyse, Travis I. Lovejoy, Adam J. Gordon, Katherine Mackey, Anders Herreid-O’Neill & Benjamin J. Morasco. (2023) “I’m Clean and Sober, But Not Necessarily Free”: Perceptions of Buprenorphine Among Patients in Long-Term Treatment. Substance Abuse 44:1-2, pages 41-50.
Crossref
Crossref
Cayley Russell, Frishta Nafeh, Michelle Pang, Shanna Farrell MacDonald, Dena Derkzen, Jürgen Rehm & Benedikt Fischer. (2022) Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study. BMC Public Health 22:1.
Crossref
Crossref
Zoe A. Karavolis & Payel J. Roy. (2022) Adapting low-dose buprenorphine induction to meet patient needs: A pilot study. Drug and Alcohol Dependence Reports 5, pages 100104.
Crossref
Crossref
Hannan M. Braun, Kristy L. Blackwood, Jeffrey P. Bratberg & Seth A. Clark. (2022) Transdermal Low-Dose Buprenorphine Induction to Transition a Patient off a Higher-Dose Methadone Regimen: a Case Report. SN Comprehensive Clinical Medicine 4:1.
Crossref
Crossref
Lauren K. Whiteside, Gail D’Onofrio, David A. Fiellin, E. Jennifer Edelman, Lynne Richardson, Patrick O’Connor, Richard E. Rothman, Ethan Cowan, Michael S. Lyons, Callan E. Fockele, Mustapha Saheed, Caroline Freiermuth, Brittany E. Punches, Clara Guo, Shara Martel, Patricia H. Owens, Edouard CoupetJr.Jr. & Kathryn F. Hawk. (2022) Models for Implementing Emergency Department–Initiated Buprenorphine With Referral for Ongoing Medication Treatment at Emergency Department Discharge in Diverse Academic Centers. Annals of Emergency Medicine 80:5, pages 410-419.
Crossref
Crossref
Leslie W. Suen, Trevor G. Lee, Michael Silva, Paulette Walton, Phillip O. Coffin, Michelle Geier & Christine S. Soran. (2022) Rapid Overlap Initiation Protocol Using Low Dose Buprenorphine for Opioid Use Disorder Treatment in an Outpatient Setting: A Case Series. Journal of Addiction Medicine 16:5, pages 534-540.
Crossref
Crossref
Linda S. Kahn, Monika L. Wozniak, Tildabeth Doscher, Cheryll Moore & Bonnie M. Vest. (2022) Treatment Experiences Among People Who Use Opioids: A Social Ecological Approach. Qualitative Health Research 32:8-9, pages 1386-1398.
Crossref
Crossref
Tara Gomes, Daniel McCormack, Nikki Bozinoff, Mina Tadrous, Tony Antoniou, Charlotte Munro, Tonya Campbell, J. Michael Paterson, Muhammad Mamdani & Beth Sproule. (2022) Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study. Addiction 117:7, pages 1972-1981.
Crossref
Crossref
Eliana Kaplowitz, Ashley Q. Truong, Justin Berk, Rosemarie A. Martin, Jennifer G. Clarke, Morgan Wieck, Josiah Rich & Lauren Brinkley-Rubinstein. (2022) Treatment preference for opioid use disorder among people who are incarcerated. Journal of Substance Abuse Treatment 137, pages 108690.
Crossref
Crossref
Lauren A. Spreen, Emma N. Dittmar, Kyle C. Quirk & Michael A. Smith. (2022) Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42:5, pages 411-427.
Crossref
Crossref
Nisha Beharie, Marissa Kaplan-Dobbs, Adelya Urmanche, Denise Paone & Alex Harocopos. (2022) “I didn't feel like a number”: The impact of nurse care managers on the provision of buprenorphine treatment in primary care settings. Journal of Substance Abuse Treatment 132, pages 108633.
Crossref
Crossref
K. K. Adams, M. Machnicz & D. M. Sobieraj. (2021) Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. Addiction Science & Clinical Practice 16:1.
Crossref
Crossref
Megan A. O’Grady, Patricia Lincourt, Belinda Greenfield, Marc W. Manseau, Shazia Hussain, Kamala Greene Genece & Charles J. Neighbors. (2021) A facilitation model for implementing quality improvement practices to enhance outpatient substance use disorder treatment outcomes: a stepped-wedge randomized controlled trial study protocol. Implementation Science 16:1.
Crossref
Crossref
Rebecca E. Stewart, Lisa Shen, Nayoung Kwon, Josh Vigderman, Susanna Kramer, David S. Mandell, Molly Candon, Roland Lamb & Aileen B. Rothbard. (2021) Transporting to treatment: Evaluating the effectiveness of a mobile engagement unit. Journal of Substance Abuse Treatment 129, pages 108377.
Crossref
Crossref
Alina Cernasev, Kenneth C. Hohmeier, Kelsey Frederick, Hilary Jasmin & Justin Gatwood. (2021) A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Exploratory Research in Clinical and Social Pharmacy 2, pages 100029.
Crossref
Crossref
Joshua A Barocas. (2021) It’s Not Them, It’s Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs. Clinical Infectious Diseases 72:8, pages 1401-1403.
Crossref
Crossref
Jessica Moe, Fiona O'Sullivan, Corinne M. Hohl, Mary M. Doyle-Waters, Claire Ronsley, Raymond Cho, Qixin Liu & Pouya Azar. (2021) Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation. Addictive Behaviors 114, pages 106740.
Crossref
Crossref
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo, S. Elise Durante, Skye P. Barbic, Daniel Lin, Steve Mathias & Pouya Azar. (2020) Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addiction Science & Clinical Practice 15:1.
Crossref
Crossref
Katharine Cioe, Breanne E. Biondi, Rebecca Easly, Amanda Simard, Xiao Zheng & Sandra A. Springer. (2020) A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. Journal of Substance Abuse Treatment 119, pages 108146.
Crossref
Crossref
Jessica Moe, Mary M. Doyle-Waters, Fiona O'Sullivan, Corinne M. Hohl & Pouya Azar. (2020) Effectiveness of micro-induction approaches to buprenorphine initiation: A systematic review protocol. Addictive Behaviors 111, pages 106551.
Crossref
Crossref
Carlos Blanco, Tisha R. A. Wiley, Jacqueline J. Lloyd, Marsha F. Lopez & Nora D. Volkow. (2020) America’s opioid crisis: the need for an integrated public health approach. Translational Psychiatry 10:1.
Crossref
Crossref
Victor M. Tang, Jessica Lam‐Shang‐Leen, Thomas D. Brothers, Keith Hansen, Alexander Caudarella, Wiplove Lamba & Tim Guimond. (2019) Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients. The American Journal on Addictions 29:1, pages 73-76.
Crossref
Crossref
Larissa J. Mooney, Jonathan Valdez, Sarah J. Cousins, Caroline Yoo, Yuhui Zhu & Yih-Ing Hser. (2020) Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results. Journal of Substance Abuse Treatment 108, pages 115-122.
Crossref
Crossref
James Bell & John Strang. (2020) Medication Treatment of Opioid Use Disorder. Biological Psychiatry 87:1, pages 82-88.
Crossref
Crossref
Margo E. Godersky, Andrew J. Saxon, Joseph O. Merrill, Jeffrey H. Samet, Jane M. Simoni & Judith I. Tsui. (2019) Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Rachel L. Snow, Rachel E. Simon, Helen E. Jack, Devin Oller, Laura Kehoe & Sarah E. Wakeman. (2019) Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. Journal of Substance Abuse Treatment 107, pages 1-7.
Crossref
Crossref
Elizabeth A. Evans, Caroline Yoo, David Huang, Andrew J. Saxon & Yih-Ing Hser. (2019) Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Journal of Substance Abuse Treatment 106, pages 19-28.
Crossref
Crossref
Nicholas Lintzeris, Anjali Bhardwaj, Llewellyn Mills, Adrian Dunlop, Jan Copeland, Iain McGregor, Raimondo Bruno, Jessica Gugusheff, Nghi Phung, Mark Montebello, Therese Chan, Adrienne Kirby, Michelle Hall, Meryem Jefferies, Jennifer Luksza, Marian Shanahan, Richard Kevin & David Allsop. (2019) Nabiximols for the Treatment of Cannabis Dependence. JAMA Internal Medicine 179:9, pages 1242.
Crossref
Crossref
Michael D. Stein, Micah T. Conti, Debra S. Herman, Bradley J. Anderson, Genie L. Bailey, Donnell Van Noppen & Ana M. Abrantes. (2019) Worries About Discontinuing Buprenorphine Treatment: Scale Development and Clinical Correlates. The American Journal on Addictions 28:4, pages 270-276.
Crossref
Crossref
Steven L. Proctor, Autumn Birch & Philip L. Herschman. (2019) Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge. Journal of Addiction Medicine 13:2, pages 113-118.
Crossref
Crossref
Matthew Hickman, Colin Steer, Kate Tilling, Aaron G. Lim, John Marsden, Tim Millar, John Strang, Maggie Telfer, Peter Vickerman & John Macleod. (2018) The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction 113:8, pages 1461-1476.
Crossref
Crossref
Zoe M. Weinstein, Gabriela Gryczynski, Debbie M. Cheng, Emily Quinn, David Hui, Hyunjoong W. Kim, Colleen Labelle & Jeffrey H. Samet. (2018) Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug and Alcohol Dependence 189, pages 166-171.
Crossref
Crossref
M. Eugenia Socías, Evan Wood, Thomas Kerr, Seonaid Nolan, Kanna Hayashi, Ekaterina Nosova, Julio Montaner & M.-J. Milloy. (2018) Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006–2016. Drug and Alcohol Dependence 189, pages 90-95.
Crossref
Crossref
Babak Tofighi, Ana Abrantes & Michael D. Stein. (2018) The Role of Technology-Based Interventions for Substance Use Disorders in Primary Care. Medical Clinics of North America 102:4, pages 715-731.
Crossref
Crossref
Ashley Elizabeth Muller, Ronny Bjørnestad & Thomas Clausen. (2018) Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug and Alcohol Dependence 187, pages 22-28.
Crossref
Crossref
M. Eugenia Socias, Keith Ahamad, Bernard Le Foll, Ron Lim, Julie Bruneau, Benedikt Fischer, T. Cameron Wild, Evan Wood & Didier Jutras-Aswad. (2018) The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. Contemporary Clinical Trials 69, pages 21-27.
Crossref
Crossref
Hari V. Kalluri, Hongfei Zhang, Steve N. Caritis & Raman Venkataramanan. (2017) A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. British Journal of Clinical Pharmacology 83:11, pages 2458-2473.
Crossref
Crossref
SAMEER HASSAMAL, MATTHEW GOLDENBERG, WAGUIH ISHAK, MARGARET HAGLUND, KAREN MIOTTO & ITAI DANOVITCH. (2017) Overcoming Barriers to Initiating Medication-assisted Treatment for Heroin Use Disorder in a General Medical Hospital: A Case Report and Narrative Literature Review. Journal of Psychiatric Practice 23:3, pages 221-229.
Crossref
Crossref
Elizabeth E. Krans & Stephen W. Patrick. (2016) Opioid Use Disorder in Pregnancy. Obstetrics & Gynecology 128:1, pages 4-10.
Crossref
Crossref
Yih‐Ing Hser, Elizabeth Evans, David Huang, Robert Weiss, Andrew Saxon, Kathleen M. Carroll, George Woody, David Liu, Paul Wakim, Abigail G. Matthews, Mary Hatch‐Maillette, Eve Jelstrom, Katharina Wiest, Paul McLaughlin & Walter Ling. (2016) Long‐term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi‐site trial. Addiction 111:4, pages 695-705.
Crossref
Crossref
Erik W. Gunderson & Michael Sumner. (2016) Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film. Journal of Addiction Medicine 10:2, pages 124-130.
Crossref
Crossref
Richard J. Bodnar. (2016) Endogenous opiates and behavior: 2014. Peptides 75, pages 18-70.
Crossref
Crossref
Petra Jacobs, Alfonso Ang, Maureen P. Hillhouse, Andrew J. Saxon, Suzanne Nielsen, Paul G. Wakim, Barbara E. Mai, Larissa J. Mooney, Jennifer S. Potter & Jack D. Blaine. (2015) Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. The American Journal on Addictions 24:7, pages 667-675.
Crossref
Crossref
Andrew J. Saxon. (2015)
Commentary on Burns
et al
. (2015): Retention in buprenorphine treatment
. Addiction 110:4, pages 656-657.
Crossref
Crossref